Correlation Analysis of MYBL2,AGR2,PAX8 and NR4A3 Expression and Clinicopathological Features and Prognosis in Bladder Cancer Tissues
Objective To analyze the expression of myeloblastoma transcription factor subtype 2(MYBL2),pre gradient protein 2(AGR2),pairing box gene 8(PAX8),and nuclear receptor subfamily 4 member 3(NR4A3)in bladder cancer and their relationship with clinicopathological characteristics and prognosis.Methods 87 patients with bladder cancer were selected.Their cancerous tissues and normal adjacent tissues(≥3cm away from the edge of the lesion)were collected and included in the obser-vation group and the control group,respectively.The MYBL2,AGR2,PAX8,NR4A3 tables of the 2 groups were detected and com-pared by immunohistochemical method to reach a difference;Collect patient age and other data,analyze the relationship between the above indicators and various clinical and pathological characteristics of patients;Followed up for 1 year to analyze the relation-ship between the expression of the four factors and patient survival rate.Results The positive expression rates of MYBL2,AGR2,and PAX8 in the observation group were higher than those in the control group,while the positive expression rates of NR4A3 were lower than those in the control group,with a statistically significant difference(P<0.05);The expression of MY-BL2,AGR2,PAX8,and NR4A3 was significantly correlated with patient differentiation,clinical stage,and lymph node metastasis(P<0.05);Followed up for 1 year,the survival rate of MYBL2,AGR2,and PAX8 positive expression patients was lower than that of negative expression patients,while the survival rate of NR4A3 positive expression patients was higher than that of negative expression patients,with a statistically significant difference(P<0.05).Conclusion MYBL2,AGR2,PAX8 and NR4A3 are ab-normally expressed in bladder cancer tissue,which are related to the differentiation degree,clinical stage,lymph node metastasis and prognosis of tumor patients,and participate in the occurrence and development of tumor.
万方数据
维普
